Neuraxis Reports Unregistered Equity Sales
Ticker: NRXS · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1933567
| Field | Detail |
|---|---|
| Company | Neuraxis, INC (NRXS) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $2.38, $5 m, $200,000, $1,135,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-securities, equity-sale
TL;DR
Neuraxis sold unregistered stock. Dilution alert!
AI Summary
Neuraxis, Inc. filed an 8-K on September 13, 2024, reporting unregistered sales of equity securities on September 9, 2024. The filing does not specify the number of shares sold or the price per share, but it indicates a transaction occurred under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates Neuraxis, Inc. has issued new equity without a prior public registration, which could impact existing shareholders through dilution.
Risk Assessment
Risk Level: medium — Unregistered sales can signal potential dilution or a need for capital, which may negatively impact stock value.
Key Players & Entities
- Neuraxis, Inc. (company) — Registrant
- September 9, 2024 (date) — Date of earliest event reported
- September 13, 2024 (date) — Filing date
- 11550 N. Meridian Street , Suite 325 Carmel , IN 46032 (address) — Principal executive offices
FAQ
What type of equity securities were sold by Neuraxis, Inc.?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities.
On what date did the unregistered sales of equity securities occur?
The earliest event reported, which corresponds to the date of the unregistered sales, is September 9, 2024.
What is the principal executive office address for Neuraxis, Inc.?
The principal executive offices are located at 11550 N. Meridian Street, Suite 325, Carmel, IN 46032.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Does the filing specify the number of shares sold or the price per share?
No, the filing does not provide specific details on the number of shares sold or the price per share for the unregistered equity securities.
Filing Stats: 1,009 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-09-13 16:33:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NRXS NYSE American Indi
- $2.38 — ferred Stock"), at a price per share of $2.38. As previously disclosed, the aggregate
- $5 m — price, as amended on March 22, 2024, is $5 million, to be paid in monthly installmen
- $200,000 — , to be paid in monthly installments of $200,000 each. The creation of the Series B Pref
- $1,135,000 — es") for an aggregate purchase price of $1,135,000. The notes were to be automatically con
- $3 million — 2024 and March 2024, in the amounts of $3 million and $2 million, respectively, with subs
- $2 m — 2024, in the amounts of $3 million and $2 million, respectively, with substantially
- $800,000 — h September 9, 2024, Flagstaff has lent $800,000 to the Company. As previously disclos
- $4,935,001.90 — 4(a) of the Preferred Stock Notes, the $4,935,001.90 of principal owed pursuant to the Prefe
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-036212.txt ( ) — 214KB
- nrxs-20240909.xsd (EX-101.SCH) — 3KB
- nrxs-20240909_lab.xml (EX-101.LAB) — 33KB
- nrxs-20240909_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 13, 2024 NEURAXIS, INC. By: /s/ Brian Carrico Name: Brian Carrico Title: President and Chief Executive Officer